Effects Of Chaplain Care On Coping With Cancer, 2024 Wayne State School of Medicine
Effects Of Chaplain Care On Coping With Cancer, Sarah Battiston, Scott L. Baughan
Clinical Research in Practice: The Journal of Team Hippocrates
A clinical case decision report using:
Piderman KM, Radecki CR, Jenkins SM, et al. Hearing and heeding the voices of those with advanced illnesses. Journal of Palliative Care. 2020;35(4):248-255. https://doi.org/10.1177/0825859720928623
for a patient having difficulty coping with cancer
Case Of Rosai Dorfman Disease In A Patient With Newly Diagnosed Hodgkin Lymphoma, 2024 The University of Texas Rio Grande Valley
Case Of Rosai Dorfman Disease In A Patient With Newly Diagnosed Hodgkin Lymphoma, Liza Salloum, Jennifer Rojas Huen, Ricardo Serna, Alisha Valdez
Research Symposium
Background: Rosai Dorfman Disease (RDD, also known as sinus histiocytosis with massive lymphadenopathy) is a rare non-Langerhans cell histiocytosis, classified into nodal (classic) and extranodal disease. Most patients present with non-tender cervical lymphadenopathy, although other sites including the inguinal and axillary regions have been reported. Extranodal disease (~43% of cases) can involve any organ system. RDD is more common in children, but cases have been reported in patients in their 70s. The prognosis of nodal RDD can correlate with the number of nodal groups involved. Many cases can be managed only with observation, although surgery, chemotherapy, corticosteroids, and immunomodulators have …
Gastric Cancer: Clinical Features, Screening, Diagnosis, Treatment, And Prevention, 2024 Department of Gastroenterology The Brooklyn Hospital Center, 121 Dekalb Avenue, Brooklyn, NY 11201
Gastric Cancer: Clinical Features, Screening, Diagnosis, Treatment, And Prevention, Rajarajeshwari Ramachandran, Tyler Grantham, Swetha Parvataneni, Deepa Budh, Sindhu Gollapalli, Madhavi Reddy, Vinaya Gaduputi
Journal of Community Hospital Internal Medicine Perspectives
The objective of this article is to highlight the clinical features, screening, diagnosis, treatment, and prevention of gastric cancer (GC). Early GC is often asymptomatic leading to frequent delays in diagnosis. Weight loss and persistent abdominal pain are the most common symptoms at initial diagnosis. The diagnosis of GC typically involves a combination of endoscopy, biopsy, and imaging studies. Endoscopic resection techniques are emerging as successful treatment options for early GC. Treatment options for advanced GC include surgery and chemotherapy. The first line chemotherapy for advanced GC consists of doublet therapy with a combination of platinum and fluoropyrimidines. Trastuzumab, a …
Breast Cancer And Colorectal Cancer Screening In Arab Americans From 2021-2023, 2024 Wayne State University School of Medicine
Breast Cancer And Colorectal Cancer Screening In Arab Americans From 2021-2023, Nicole Oska, Hasti Nema, Deni Peterson, Kendall Brothers, Mohammed Najeeb Al Hallek
Medical Student Research Symposium
Breast Cancer and Colorectal Cancer Screening in Arab Americans from 2021-2023
Nicole Oska1, Hasti Nema1, Deni Peterson1, Kendall Brothers1, Mohammed Najeeb Al Hallak1,2
1Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, USA; 2Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
Introduction:
Breast cancer (BC) and colorectal cancer (CRC) are among the most commonly diagnosed cancers in the United States1,2; screening for these cancers is a pivotal component of preventative healthcare. Arab Americans represent a diverse, yet understudied, patient population that may encounter distinct barriers …
Flash Radiation Ultra-High Dose Rate Radiation With Potential For Sensitization By Platinum, 2024 Wayne State University
Flash Radiation Ultra-High Dose Rate Radiation With Potential For Sensitization By Platinum, Abigail A. Jaczkowski, Stephen Brown Ph.D.
Medical Student Research Symposium
External beam radiation therapy, a cornerstone in cancer treatment for 50% of patients, poses challenges due to its toxicity to both cancer and healthy cells. Seeking to mitigate side effects, the emerging FLASH radiation technology employs ultra-high dose rates, promising quicker treatments with reduced impact on surrounding normal tissue. Platinum, recognized as a radiation sensitizer, enhances the effectiveness of radiation therapy by increasing sensitization at higher energy levels through pair-production.
This study explores the hypothesis that Cisplatin, a platinum-based chemotherapy agent, will exhibit a synergistic effect when combined with FLASH radiation. Using A549 cells from non-small cell lung cancer, the …
Analysis Of Antibody Drug Conjugate On Cellular Senescent Human Glioblastoma, 2024 Wayne State University
Analysis Of Antibody Drug Conjugate On Cellular Senescent Human Glioblastoma, Ariel P. Walker, Renee Hirte, Cecile Riviere-Cazaux, Authur Warrington, Terry Burns
Medical Student Research Symposium
Background: Glioblastoma Multiforme (GBM) is an aggressive and malignant brain tumor known for its rapid progression and unfavorable prognosis. The standard treatment options primarily involve radiation and temozolomide, however recurrence is inevitable.
B7H3/CD276, an immunomodulatory transmembrane glycoprotein, demonstrates tumor-specific expression, with limited presence in normal healthy tissue, making it a promising and attractive treatment target in GBM. AbbV155 is an antibody drug conjugate that inhibits BCL-XL and specifically targets B7H3 (CD276) on GBM cells with the goal of selectively eliminating viable tumor cells.
Objectives: First, we sought to confirm the presence of B7H3/CD276 in our selected cell line via …
Primary Mucinous Carcinoma Of The Thyroid: A Case Report, Literature Review, And Immunohistochemistry Summary, 2024 Grand Strand Medical Center
Primary Mucinous Carcinoma Of The Thyroid: A Case Report, Literature Review, And Immunohistochemistry Summary, Martin T. Halicek, Caleb Scott, Terence Zimmermann, Brian Watson
HCA Healthcare Journal of Medicine
Introduction
Primary mucinous carcinoma of the thyroid is an exceedingly rare malignancy that is histologically similar to mucinous carcinoma of other sites. Accurate diagnosis is a challenging yet crucial component of clinical management for both patients and our understanding of this rare disease.
Case Presentation
We report the case of a 69-year-old male patient with primary mucinous carcinoma of the thyroid. Microscopic examination of a biopsy specimen showed fibrous tissue, which was extensively and irregularly infiltrated by a cytologically malignant epithelial neoplasm showing glandular differentiation with mucin production. Immunohistochemistry demonstrated that tumor cells were positive for TTF1, thyroglobulin, CK7, and …
Social Needs Risk And Patient Outcomes With Supportive Oncology Care, 2024 Thomas Jefferson University
Social Needs Risk And Patient Outcomes With Supportive Oncology Care, Rebecca Cammy, Lcsw, Joshua Banks, Ma
Department of Medical Oncology Posters
Objective
This study utilized social risk data in the electronic heath record collected in routine clinical practice and examined relationships with supportive oncology care contacts and patient outcomes.
Repurposing Of Us-Fda-Approved Drugs As Negative Modulators Of Ubiquitin Specific Protease-7 (Usp7), 2024 University of Karachi
Repurposing Of Us-Fda-Approved Drugs As Negative Modulators Of Ubiquitin Specific Protease-7 (Usp7), Seema Zadi, Sumaira Javaid, Atia-Tul-Wahab, Humaira Zafar, Muhammad Awais, Innokentiy Maslennikov, M. Iqbal Choudhary
Pharmacy Faculty Articles and Research
Ubiquitin-specific protease7 (USP7) regulates the stability of the p53 tumor suppressor protein and several other proteins critical for tumor cell survival. Aberrant expression of USP7 facilitates human malignancies by altering the activity of proto-oncogenes/proteins, and tumor suppressor genes. Therefore, USP7 is a validated anti-cancer drug target. In this study, a drug repurposing approach was used to identify new hits against the USP7 enzyme. It is one of the most strategic approaches to find new uses for drugs in a cost- and time-effective way. Nuclear Magnetic Resonance-based screening of 172 drugs identified 11 compounds that bind to the catalytic domain of …
Angiofibroma Of Soft Tissue: A Case Report, 2024 Noorda College of Osteopathic Medicine
Angiofibroma Of Soft Tissue: A Case Report, Mehruba Alam, Jake Robins
Annual Research Symposium
Differentiation between benign angiofibromas of soft tissue and malignant sarcomas.
The accurate diagnosis of this tumor is essential to prevent additional unnecessary treatments and/or surgeries. This can be achieved by proper genetic testing for the presence of markers including the NCOA2 fusion gene, CD34, α-SMA, and epithelial membrane antigen. Genetic testing is an essential component of accurate diagnosis as the appearance of these lesions can mimic other, more harmful neoplasms. Immunohistochemical analysis frequently shows the AHRR-NCOA2 driver mutation which is thought to be associated with t(5;8)(p15;q13), also commonly found in AFSTs. In combination, these immunohistochemical findings allow for accurate diagnosis …
Challenges In Diagnosing Hepatic Epithelioid Hemangioendothelioma: A Case Series, 2024 Noorda College of Osteopathic Medicine
Challenges In Diagnosing Hepatic Epithelioid Hemangioendothelioma: A Case Series, Aratara Nutcharoen, Elliott Beard, Anupa Thirmiya, Omar Taher, Jacob Adams, Mark Mortensen, John Pelham, Aratara Nutcharoen
Annual Research Symposium
Challenges in Diagnosing Hepatic Epithelioid Hemangioendothelioma
Molecular-Guided Therapy For The Treatment Of Patients With Relapsed And Refractory Childhood Cancers: A Beat Childhood Cancer Research Consortium Trial., 2024 Children's Mercy Kansas City
Molecular-Guided Therapy For The Treatment Of Patients With Relapsed And Refractory Childhood Cancers: A Beat Childhood Cancer Research Consortium Trial., Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C. Lewis, Jacqueline Kraveka, William Ferguson, Abhinav B. Nagulapally, Karl Dykema, Valerie I Brown, Michael S. Isakoff, Joseph Junewick, Deanna Mitchell, Jawhar Rawwas, William Roberts, Don Eslin, Javier Oesterheld, Randal K. Wada, Devang Pastakia, Virginia Harrod, Kevin Ginn, Raya Saab, Kevin Bielamowicz, Jason Glover, Eugenia Chang, Gina K. Hanna, Daniel Enriquez, Tyler Izatt, Rebecca F Halperin, Abigail Moore, Sara A. Byron, William P D Hendricks, Jeffrey M. Trent
Manuscripts, Articles, Book Chapters and Other Papers
BACKGROUND: Children with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This prospective clinical trial examined the feasibility of combining genomic and transcriptomic profiling of tumor samples with a molecular tumor board (MTB) approach to make real‑time treatment decisions for children with relapsed/refractory solid tumors.
METHODS: Subjects were divided into three strata: stratum 1-relapsed/refractory neuroblastoma; stratum 2-relapsed/refractory CNS tumors; and stratum 3-relapsed/refractory rare solid tumors. Tumor samples were sent for tumor/normal whole-exome (WES) and tumor whole-transcriptome (WTS) sequencing, and the genomic data were used in a multi-institutional MTB to make real‑time treatment …
Access To Surgical Treatment For Hepatopancreaticobiliary Cancer In The Philippines, 2024 Ateneo de Manila University
Access To Surgical Treatment For Hepatopancreaticobiliary Cancer In The Philippines, Luis Miguel B. Co, F. Lorenzo Martin A. Puno, Erika P. Ong, Frances Dominique V. Ho, Michelle Ann B. Eala, Edward Christopher Dee, Ethan Angelo S. Maslog, Ryan T. Barroso, T. Peter Kingham, Samuel D. Ang, Christian Daniel U. Ang
Ateneo School of Medicine and Public Health Publications
Hepatopancreaticobiliary cancers are among the most diagnosed cancers in the world. However, although high-income countries have the highest incidence rates, low- and middle-income countries have the highest mortality rates. In this article, we describe the geographic distribution of board-certified hepatopancreaticobiliary surgeons who provide surgical management for patients with these diseases in the Philippines. We draw attention to the geographic disparities in the distribution of these surgeons and the other factors that contribute to the lack of access. Lastly, we suggest ways forward.
Prognostic Properties Of Kras Gene Mutation Subtypes In Resected Pancreatic Cancer, 2024 Thomas Jefferson University
Prognostic Properties Of Kras Gene Mutation Subtypes In Resected Pancreatic Cancer, Faria Nusrat, Eliyahu Gorgov, Md, Wilbur Bowne, Md, Obehioye Isesele, Akshay Khanna, Harish Lavu, Md, Aditi Jain, Phd, Charles J. Yeo, Md, Avinoam Nevler, Md
Alpha Omega Alpha Research Symposium Posters
Introduction
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and therapy-resistant cancer with an overall 5-year survival rate of almost 12%, making it among the most lethal of all major cancers.1
- PDAC has a distinct genomic profile, with somatic KRAS protooncogene mutations in ~90% of cases.2,3
- Current literature has not reached a consensus on disease prognosis based on KRAS mutation subtype.2-5
Avaren-Fc, A Novel Immunotherapeutic, Recruits Nk Cells In B16f10 Melanoma Tumor Tissue, 2024 University of Louisville
Avaren-Fc, A Novel Immunotherapeutic, Recruits Nk Cells In B16f10 Melanoma Tumor Tissue, Sreevatsa Vemuri, Katarina Mayer, Nobuyuki Matoba
Posters-at-the-Capitol
Melanoma is the fifth most common cancer in the US, with limited effective immunotherapeutic options available for patients. Avaren-Fc (AvFc) is a novel experimental immunotherapeutic agent with a unique “lectibody” property. It is capable of targeting cancer cells through the selective recognition of high mannose glycans, which are aberrantly overrepresented on the surface of malignant cells. AvFc can interact with circulating effector immune cells equipped with Fc receptors, such as natural killer (NK) cells to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and kill cancer cells. Previous work has shown that AvFc effectively induces ADCC activity against B16F10 cancer cells in vitro …
Classification Of Colorectal Cancer Using Resnet And Efficientnet Models, 2024 Vellore Institute of Technology
Classification Of Colorectal Cancer Using Resnet And Efficientnet Models, Abhishek Ranjan, Priyanshu Srivastva, B Prabadevi, R Sivakumar, Rahul Soangra, Shamala K. Subramaniam
Physical Therapy Faculty Articles and Research
Introduction:
Cancer is one of the most prevalent diseases from children to elderly adults. This will be deadly if not detected at an earlier stage of the cancerous cell formation, thereby increasing the mortality rate. One such cancer is colorectal cancer, caused due to abnormal growth in the rectum or colon. Early screening of colorectal cancer helps to identify these abnormal growth and can exterminate them before they turn into cancerous cells.
Aim:
Therefore, this study aims to develop a robust and efficient classification system for colorectal cancer through Convolutional Neural Networks (CNNs) on histological images.
Methods:
Despite challenges in …
Therapeutic Antibodies For The Prevention And Treatment Of Cancer, 2024 Thomas Jefferson University
Therapeutic Antibodies For The Prevention And Treatment Of Cancer, Mukesh Kumar, Akansha Jalota, Sushil Kumar Sahu, Shabirul Haque
Department of Medical Oncology Faculty Papers
The developments of antibodies for cancer therapeutics have made remarkable success in recent years. There are multiple factors contributing to the success of the biological molecule including origin of the antibody, isotype, affinity, avidity and mechanism of action. With better understanding of mechanism of cancer progression and immune manipulation, recombinant formats of antibodies are used to develop therapeutic modalities for manipulating the immune cells of patients by targeting specific molecules to control the disease. These molecules have been successful in minimizing the side effects instead caused by small molecules or systemic chemotherapy but because of the developing therapeutic resistance against …
Chlormethine Gel In Combination With Other Therapies For Treatment Of Mycosis Fungoides: A Review With Patient Cases, 2024 Thomas Jefferson University
Chlormethine Gel In Combination With Other Therapies For Treatment Of Mycosis Fungoides: A Review With Patient Cases, Marco Ardigò, Neda Nikbakht, Miriam Teoli, Laura Gleason, Liliana Crisan, Christiane Querfeld
Department of Dermatology and Cutaneous Biology Faculty Papers
Topical chlormethine gel has been approved as monotherapy for treatment of adult patients with mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma. In clinical practice, chlormethine gel is often combined with other skin-directed or systemic therapies to optimize response and target recalcitrant lesions. Positive outcomes with combination regimens using chlormethine gel and topical corticosteroids, phototherapy, retinoids, methotrexate, or interferon-α have been reported in literature. However, there are no treatment guidelines on the use of combination regimens with chlormethine gel. To provide real-world evidence and guidance on the use of chlormethine gel combination regimens, several cases of patients …
Search Strategies For "Community Engagement Definition And Evaluation For Cancer Center: Scoping Review", 2024 University of Nebraska Medical Center
Search Strategies For "Community Engagement Definition And Evaluation For Cancer Center: Scoping Review", Heidi Keeler, Brooke Fitzpatrick, Nicole Carritt, Emma Hymel, Josiane Kabayundo, Jordan Mccullough, Krishtee Napit, Regina Idoate, Shinobu Watanabe-Galloway
Search Strategies
No abstract provided.
Regulatory Approval Of Clinical Trials: Is It Time To Reinvent The Wheel?., 2024 Aga Khan University
Regulatory Approval Of Clinical Trials: Is It Time To Reinvent The Wheel?., Mansoor Saleh, Karishma Sharma, Aisleen Shamshudin, Innocent Abayo, Stacey Gondi, Noureen Karimi
Internal Medicine, East Africa
Less than 1% of all clinical trials are conducted in Africa. In 2019, only six of 26 oncology clinical trials conducted in Africa were conducted in countries with subjects of African ancestry. There are multiple barriers that hinder the conduct of cancer clinical trials in Africa. Time to trial activation (TTA) is the administrative and regulatory process required before a study can be activated—an important metric and often a major barrier for site selection. In Kenya, TTA involves review by Institutional Review Board (IRB), Pharmacy and Poisons Board, National Commission for Science, Technology and Innovation and Ministry of Health, all …